Courtagen | GenomeWeb


Courtagen will use its ZiPhyr bioinformatics pipeline to help Astellas develop a predictive model that can be used in early-stage drug development.

The life sciences company can now offer its genetic tests in all 50 states in the US, as well as Canada and several other countries. 

Courtagen Raises $20M

Proceeds from the financing will be used "to expand our ability to deliver leading-edge services to our customers," Courtagen's CEO said. 

A spokesman for Courtagen, which develops NGS-based tests for ailments such as mitochondrial disorders, the $7.5 million is part of a financing round expected to bring in about $17 million. 

The deals are with Pronto Diagnostics, headquartered in Tel Aviv, Israel and Medica Labs, based in Bangkok, Thailand.

NEW YORK (GenomeWeb) – Courtagen Life Sciences today announced a deal with Bioinn Molecular Diagnosis to provide Courtagen's clinical next-generation sequencing tests for neurological and metabolic disorders in Taiwan.

NEW YORK (GenomeWeb) – Courtagen Life Sciences has raised about $6.3 million, the genetic testing firm disclosed in a document filed with the US Securities and Exchange Commission this week.

NEW YORK (GenomeWeb) – Courtagen Life Sciences said today that it has partnered with Sciencewerke for the international distribution of its clinical next-generation sequencing tests.

As CSO of Woburn, Mass.-based genetic testing firm Courtagen, Kevin McKernan recently co-authored a

NEW YORK (GenomeWeb) — Courtagen Life Sciences will collaborate with Connecticut Children's Medical Center to identify alterations in genes associated with Autism Spectrum Disorder.


In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.